title: Piracetam and dyslexia: effects on reading tests.
abstract: Previous research has suggested that dyslexics treated with piracetam have shown improvements in reading skills, verbal memory and verbal conceptualizing ability, feature analysis, and processing of letter-like stimuli. Two hundred twenty-five dyslexic children between the ages of 7 years 6 months and 12 years 11 months whose reading skills were significantly below their intellectual capacity were enrolled in a multicenter, 36-week, double-blind, placebo-controlled study. Children of below average intelligence, with abnormal findings on audiologic, ophthalmologic, neurologic, psychiatric, and physical examinations, who were emotionally disturbed or educationally deprived and who had recently been treated with psychoactive medication were excluded from the trial. Piracetam was well tolerated, with no serious adverse clinical or laboratory effects reported. Piracetam-treated children showed significant improvements in reading ability (Gray Oral Reading Test) and reading comprehension (Gilmore Oral Reading Test). Treatment effects were evident after 12 weeks and were sustained for the total period (36 weeks).
authors.forename: C R
authors.initials: CR
authors.lastname: Wilsher
authors.forename: D
authors.initials: D
authors.lastname: Bennett
authors.forename: C H
authors.initials: CH
authors.lastname: Chase
authors.forename: C K
authors.initials: CK
authors.lastname: Conners
authors.forename: M
authors.initials: M
authors.lastname: DiIanni
authors.forename: L
authors.initials: L
authors.lastname: Feagans
authors.forename: L J
authors.initials: LJ
authors.lastname: Hanvik
authors.forename: E
authors.initials: E
authors.lastname: Helfgott
authors.forename: H
authors.initials: H
authors.lastname: Koplewicz
authors.forename: P
authors.initials: P
authors.lastname: Overby
mesh_terms: D002648:Child; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004410:Dyslexia / Q000188:drug therapy* / Q000523:psychology; D005260:Female; D006801:Humans; D008297:Male; D010889:Piracetam / Q000009:adverse effects / Q000627:therapeutic use*; D011760:Pyrrolidinones / Q000627:therapeutic use*; D011897:Random Allocation; D011932:Reading
chemical_list: D011760:Pyrrolidinones; D010889:Piracetam